RJA
TRAW icon

Raymond James & Associates’s Traws Pharma TRAW Stock Holding History

Raymond James & Associates’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-103
Closed -$38K – 4231
2021
Q1 		$38K Hold
103
– – ﹤0.01% 3874
2020
Q4 		$18K Hold
103
– – ﹤0.01% 3696
2020
Q3 		$11K Buy
+103
New +$25.5K ﹤0.01% 3541

Other funds holding TRAW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

Raymond James & Associates's TRAW Position: Q2 2021 in Review

Raymond James & Associates sold out of Traws Pharma (TRAW) in Q2 2021, closing a stake of 103 shares — an estimated $38K sold.

Raymond James & Associates first reported a position in TRAW in Q3 2020 and held it in 3 quarters. The position peaked at $38K in Q1 2021. 25 funds tracked by Wall St. Rank hold TRAW as of Q2 2021.

  • Raymond James & Associates reported no remaining Traws Pharma position as of Q2 2021 after selling out during the quarter.
  • Raymond James & Associates sold 103 Traws Pharma shares in Q2 2021, an estimated $38K.
  • Raymond James & Associates first reported a position in Traws Pharma in Q3 2020 and held it in 3 quarters.
  • Raymond James & Associates's Traws Pharma position peaked at $38K in Q1 2021.
  • 25 funds tracked by Wall St. Rank held Traws Pharma as of Q2 2021.

Based on Raymond James & Associates's 13F filing for Q2 2021, filed 11 Aug 2021.